Early-onset myasthenia gravis (EOMG) and early-onset Parkinson's disease (EOPD) are rare diseases, and few studies have been reported on these diseases. The paper reported the diagnosis progress of a case of EOMG combined with EOPD, then introduced the diagnostic criteria, clinical features and pathogenesis of the two diseases, intending to enhance clinicians' understanding of the two diseases and improve the diagnostic correctness of the combination of the two diseases.

1.Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies[J]. Lancet Neurol, 2015, 14(10): 1023-1036. DOI: 10.1016/s1474-4422(15)00145-3.

2.Alkhawajah NM, Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing[J]. Muscle Nerve, 2013, 48(5): 705-710. DOI: 10.1002/mus.23964.

3.Murphy KT, Lynch GS. Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments[J]. J Cachexia Sarcopenia Muscle, 2023, 14(5): 1987-2002. DOI: 10.1002/jcsm.13312.

4.Li M, Wan J, Xu Z, et al. The association between Parkinson's disease and autoimmune diseases: a systematic review and Meta-analysis[J]. Front Immunol, 2023, 14: 1103053. DOI: 10.3389/fimmu.2023.1103053.

5.Sangarapillai K, Norman BM, Almeida QJ. An equation to calculate UPDRS motor severity for online and rural assessments of Parkinson's[J]. Parkinsonism Relat Disord, 2022, 94: 96-98. DOI: 10.1016/j.parkreldis.2021.11.028.

6.Chen YS, Chen MH, Lu CH, et al. Associations among cognitive functions, plasma DNA, and white matter integrity in patients with early-onset Parkinson's disease[J]. Front Neurosci, 2017, 11: 9. DOI: 10.3389/fnins.2017.00009.

7.Gregersen PK, Kosoy R, Lee AT, et al. Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08[J]. Ann Neurol, 2012, 72(6): 927-935. DOI: 10.1002/ana.23691.

8.Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity[J]. Lancet Neurol, 2009, 8(5): 475-490. DOI: 10.1016/s1474-4422(09)70063-8.

9.Zhu W, Huang X, Yoon E, et al. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease[J]. Brain, 2022, 145(6): 2077-2091.DOI: 10.1093/brain/awab456.

10.Thanprasertsuk S, Phowthongkum P, Hopetrungraung T, et al. Levodopa-induced dyskinesia in early-onset Parkinson's disease (EOPD) associates with glucocerebrosidase mutation: a next-generation sequencing study in EOPD patients in Thailand[J]. PloS One, 2023, 18(10): e0293516. DOI: 10.1371/journal.pone.0293516.

11.Hui T, Guo S. Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report[J]. J Med Case Rep, 2023, 17(1): 405. DOI: 10.1186/s13256-023-04147-x.

12.Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy[J]. N Engl J Med, 1999, 340(18): 1443. DOI: 10.1056/nejm199905063401817.

13.Ferguson LW, Rajput AH, Rajput A. Early-onset vs. late-onset parkinson's disease: a clinical-pathological study[J]. Can J Neurol Sci, 2016, 43(1): 113-119. DOI: 10.1017/cjn.2015.244.

14.Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease[J]. Nat Rev Immunol, 2022, 22(11): 657-673. DOI: 10.1038/s41577-022-00684-6.

15.Bovenzi R, Conti M, Degoli GR, et al. Shaping the course of early-onset Parkinson's disease: insights from a longitudinal cohort[J]. Neurol Sci, 2023, 44(9): 3151-3159. DOI: 10.1007/s10072-023-06826-5.

16.段松堂, 卢威, 喻巍, 等. 绿原酸抑制NF-κB/NLRP3炎性体通路减轻LPS诱导小胶质细胞神经炎症损伤研究[J]. 中国药师, 2022, 25(5): 758-764. [Duan ST, Lu W, Yu W, et al. Chlorogenic acid reducing LPS-induced neuroinflammatory injury in microglia by inhibiting NF-κB/NL-RP3 inflammasome pathway[J]. China Pharmacist, 2022, 25(5): 758-764.] DOI: 10.19962/j.cnki.issn1008-049X.2022.05.002.

17.谢琰臣, 孙兆林, 丛志强. 帕金森病合并重症肌无力一例报告[J]. 中国神经免疫学和神经病学杂志, 2003, 10(3): 185. [Xie YC, Sun ZL, Cong ZQ. A case report of Parkinson's disease combined with myasthenia gravis[J]. Chinese Journal of Neuroimmunology and Neurology, 2003, 10(3): 185.] DOI: 10.3969/j.issn. 1006-2963.2003. 03.027.

18.Odajiu I, Davidescu EI, Mitu C, et al. Patients with Parkinson's disease and myasthenia gravis-a report of three new cases and review of the literature[J]. Medicina (Kaunas), 2019, 56(1): 5. DOI: 10.3390/medicina56010005.

19.Song Z, Li W, Han Y, et al. Association of immune cell traits with Parkinson's disease: a Mendelian randomization study[J]. Front Aging Neurosci, 2024, 16: 1340110. DOI: 10.3389/fnagi.2024.1340110.

20.McFleder RL, Makhotkina A, Groh J, et al. Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson's disease[J]. Nat Commun, 2023, 14(1): 7529. DOI: 10.1038/s41467-023-43224-z.

21.Tang C, Lei X, Ding Y, et al. Causal relationship between immune cells and neurodegenerative diseases: a two-sample Mendelian randomisation study[J]. Front Immunol, 2024, 15: 1339649. DOI: 10.3389/fimmu.2024.1339649.

22.Nimmo J, Byrne Robert AJ, Daskoulidou N, et al. The complement system in neurodegenerative diseases[J]. Clin Sci(Lond), 2024, 138(6): 387-412. DOI: 10.1042/cs20230513.

23.Morrone Parfitt G, Coccia E, Goldman C, et al. Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model[J]. Nat Commun, 2024, 15(1): 447. DOI: 10.1038/s41467-024-44732-2.

24.Mosley RL, Hutter-Saunders JA, Stone DK, et al. Inflammation and adaptive immunity in Parkinson's disease[J]. Csh Perspect Med, 2011, 2(1): a009381. DOI: 10.1101/cshperspect.a009381.

25.Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders[J]. Eur J Neurol, 2010, 17(7): 893-902. DOI: 10.1111/j.1468-1331.2010.03019.x.

26.De Virgilio A, Greco A, Fabbrini G, et al. Parkinson's disease: autoimmunity and neuroinflammation[J]. Autoimmun Rev, 2016, 15(10): 1005-1011. DOI: 10.1016/j.autrev.2016.07.022.

27.Al-Bachari S, Naish JH, Parker GJM, et al. Blood-brain barrier leakage is increased in Parkinson's disease[J]. Front Physiol, 2020, 11: 593026. DOI: 10.3389/fphys.2020. 593026.